CLINICAL TRIALS PROFILE FOR ESKALITH

All Clinical Trials for ESKALITH

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00057681 ↗	Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents	Completed	National Institute of Mental Health (NIMH)	Phase 3	2003-02-01	This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 ↗	Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents	Completed	Washington University School of Medicine	Phase 3	2003-02-01	This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00221975 ↗	Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling	Completed	University Hospitals Cleveland Medical Center	Phase 3	2002-07-01	Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a combination of lithium and divalproex. Once these medications are tolerated, they are randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in this study until they experience a marked bimodal response for four consecutive weeks. This study is sponsored by the Stanley Foundation.
NCT00408681 ↗	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Completed	National Cancer Institute (NCI)	N/A	2006-06-01	RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
NCT00408681 ↗	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Completed	Fred Hutchinson Cancer Research Center	N/A	2006-06-01	RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.

Clinical Trial Conditions for ESKALITH

Condition Name

Condition Name for ESKALITH
Intervention	Trials
Bipolar Disorder	7
Late Life Depression	2
Treatment-Refractory Depression	2
Major Depressive Disorder	2

Condition MeSH

Condition MeSH for ESKALITH
Intervention	Trials
Bipolar Disorder	8
Depressive Disorder	3
Depression	3
Depressive Disorder, Major	3

Clinical Trial Locations for ESKALITH

Trials by Country

Trials by Country for ESKALITH
Location	Trials
United States	28
Canada	3
Sweden	2
Norway	1

Trials by US State

Trials by US State for ESKALITH
Location	Trials
Ohio	4
California	3
Pennsylvania	3
Missouri	3
New York	2

Clinical Trial Progress for ESKALITH

Clinical Trial Phase

Clinical Trial Phase for ESKALITH
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for ESKALITH
Clinical Trial Phase	Trials
Completed	10
Terminated	1
Active, not recruiting	1

Clinical Trial Sponsors for ESKALITH

Sponsor Name

Sponsor Name for ESKALITH
Sponsor	Trials
National Institute of Mental Health (NIMH)	5
Washington University School of Medicine	2
University Hospitals Cleveland Medical Center	2

Sponsor Type

Sponsor Type for ESKALITH
Sponsor	Trials
Other	13
NIH	7
Industry	2